Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100OW8K
Period2022-04-01 → 2022-06-30
Filed2022-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥143.5bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥142.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥452m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥377m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥644m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥674m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥314.2bnat 2022-06-30Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥333.7bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥212.9bnat 2022-06-30Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥106.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥27.9bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥11.672021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥389m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥118m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.1bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥521m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥146.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥452m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-06-30¥1.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-06-30¥1.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-06-30−¥45m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.8bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥13m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2021-04-01 → 2021-06-30¥137.0bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2021-04-01 → 2021-06-30¥134.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2021-04-01 → 2021-06-30¥290m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.4bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥39m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥2.6bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥106m
—segment totalrevenue2021-04-01 → 2021-06-30¥144.0bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥141.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.2bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥437m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥145.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥142.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥391m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 370
ItemContextValueUnit
Profit loss attributable to owners of parentPrior1YTDDuration644000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration640000000JPY
Profit lossPrior1YTDDuration674000000JPY
Profit lossCurrentYTDDuration675000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration1625000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2234000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-97000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-89000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration25000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration247000000JPY
Other comprehensive incomePrior1YTDDuration1553000000JPY
Other comprehensive incomeCurrentYTDDuration2392000000JPY
Comprehensive incomePrior1YTDDuration2228000000JPY
Comprehensive incomeCurrentYTDDuration3068000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration2198000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration3032000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration29000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration35000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember134777000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember4437000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember2581000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember141796000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1119000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember142916000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration142916000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember2211000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember1000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember0JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember2212000000JPY
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember626000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember2839000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-2839000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember136988000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember4438000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember2581000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember144008000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember1746000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember145755000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-2839000000JPY
Net salesPrior1YTDDuration142916000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E22440-000MedicineWholesaleReportableSegmentMember290000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E22440-000PharmacyBusinessReportableSegmentMember39000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E22440-000VeterinaryDrugsWholesaleBusinessReportableSegmentMember106000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember437000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-45000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember391000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-13000000JPY
Operating incomePrior1YTDDuration377000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass